Targeted Oncology™ Launches “Targeted Talks” Podcast Series

CRANBURY, N.J.--(BUSINESS WIRE)--Targeted Oncology™, a multimedia resource that offers informative content and expert opinions on standard and emerging treatments in the field of oncology, announces the launch of its new podcast series, “Targeted Talks.”

“We are excited to announce the launch of our upcoming podcast series, 'Targeted Talks,'” said Mike Hennessy Jr., president and CEO of MJH Life Sciences™, parent company of Targeted Oncology™. “This monthly podcast allows our listeners to hear from community and academic oncologists in the field as they discuss hot topics in oncology and hematology, and we look forward to hearing them share their expert insights and learning as they work toward a common goal of making strides and advancements in oncology.”

To kick off the first episode, Jason A. Williams, M.D., of Williams Cancer Institute, and George R. Simon, M.D., FACO, FCCP, of MD Anderson Cancer Center, will discuss immunotherapy use in patients with non–small cell lung cancer and a genetic driver, view the episode here.

Every month, Targeted Talks will work with leading academic and community oncologists to provide the latest updates and research surrounding advancements in cancer research and best practices for patient management. In the next two episodes, leading oncology experts will delve into detailed discussions on hot topics of liquid vs tumor biopsies, as well as the latest advancements within ovarian cancer.

Click here for more information on the “Targeted Talks” podcast series.

About Targeted Oncology™

TargetedOnc.com, the website for Targeted Oncology™, provides practicing oncologists with the latest news and insights on next-generation therapeutics and their molecular targets. As the field of oncology moves toward systemic biology and molecular aberrations, oncologists may struggle to stay up to date with cancer therapeutics. Targeted Oncology™ provides breaking news and updates on this burgeoning field, focusing on the next stage of cancer development, cutting-edge therapies and biological targets. Content is organized by tumor type, news and conference coverage.